Table 1.
Baseline demographic characteristics
| Characteristic |
Vericiguat + nitroglycerin n = 24 |
Placebo + nitroglycerin n = 12 |
|---|---|---|
| Sex, n (%) | ||
| Male | 21 (87.5) | 12 (100.0) |
| Female | 3 (12.5) | 0 (0.0) |
| Race, n (%) | ||
| White | 24 (100.0) | 12 (100.0) |
| Age in years, mean (range) | 62.4 (47–79) | 62.5 (46–74) |
| Weight, kg | 89.6 (11.1) | 83.1 (13.1) |
| Height, cm | 174.5 (6.3) | 175.3 (4.2) |
| BMI, kg/m2 | 29.4 (3.4) | 27.0 (4.1) |
| SBP, mmHg a | 126.7 (17.6) | 119.8 (16.6) |
| DBP, mmHg a | 73.0 (10.5) | 71.4 (8.7) |
| Seated HR, bpm a | 68.5 (10.9) | 66.8 (10.2) |
| Medical history | ||
| Patients with cardiac disorders, n (%) | 24 (100.0) | 12 (100.0) |
| CAD (CCS) b | 23 (95.8) | 11 (91.7) |
| Chronic HF | 2 (8.3) | 2 (16.7) |
| Acute MI c | 9 (37.5) | 5 (41.7) |
| MI | 10 (41.7) | 7 (58.3) |
Data are mean (SD), unless indicated otherwise.
BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; CCS, chronic coronary syndrome; DBP, diastolic blood pressure; HF, heart failure; HR, heart rate; MedDRA, Medical Dictionary for Regulatory Activities; MI, myocardial infarction; SBP, systolic blood pressure; SD, standard deviation.
Baseline measurements taken on Day 0 (defined as the last predose measurement performed prior to the first administration of study medication).
According to protocol‐defined inclusion and exclusion criteria.
Acute MI: occurred > 6 months prior to the first screening examination (exclusion criterion 2). MI coded by MedDRA.